



→ Nazia J. Khan

Associate

2099 Pennsylvania Avenue, N.W.
Suite 100
Washington, DC 20006-6801

T: +1.202.747.2651

nkhan@sheppardmullin.com

Nazia Khan is an associate in the Corporate Practice Group in the firm's Washington D.C. office.

Areas of Practice

Ms. Khan's practice focuses on corporate finance and securities laws. Ms. Khan represents underwriters and companies in various industries including technology, cannabis, life sciences, healthcare, food and beverage, transportation and REITs in capital markets transactions. Her experience includes leading both underwriters as well as domestic and foreign companies in public and private corporate finance transactions, including initial public offerings, shelf registrations, registered direct transactions, private investments in public equity (PIPEs), private placements and other securities offerings. In addition, Ms. Khan's experience includes initial public offerings of SPACs as well as de-SPAC transactions. She also represents publicly held companies with their reporting obligations under the Exchange Act and with NASDAQ, NYSE and other exchange listing and compliance matters including matters involving FINRA.

Honors

New York Metro Rising Stars, *Super Lawyers*, 2017-2022

Ones to Watch – Corporate Law, *Best Lawyers*, 2021, 2022

Who's Who in America, 2019

Experience

Traditional IPOs:

- Represented Syra Health Corp. in its initial public offering and listing on Nasdaq
- Represented Immix Biopharma, Inc. in its initial public offering and listing on Nasdaq
- Represented Greenwich LifeSciences, Inc. in its initial public offering and listing on Nasdaq
- Represented Hoth Therapeutics, Inc. in its initial public offering and listing on Nasdaq
- Represented Immuron Limited in its initial public offering and listing on Nasdaq
- Represented Aridis Pharmaceuticals, Inc., in its initial public offering and listing on Nasdaq
- Represented underwriters in an initial public offering and listing on Nasdaq of a company in the rideshare industry

- Represented underwriters in an initial public offering of and listing on Nasdaq of a biotechnology company focused on early cancer screening and detection

SPACs:

- Represented A.G.P./Alliance Global Partners in an initial public offering and listing on NYSE American of Ault Disruptive Technologies Corporation
- Represented A.G.P./Alliance Global Partners in an initial public offering and listing on Nasdaq of Digital Health Acquisition Corp.

Other Transactions:

- Represented LKQ Corp. (Nasdaq: LKQ) in a 144A offering of senior unsecured notes in the aggregate principal amount of \$1.4 billion
- Represented Majesco in sale to private equity firm for \$729 million

Articles

Corporate and Securities Law Blog Posts

- "SEC Adopts Amendments Regarding Insider Trading Plans and Related Disclosures," January 10, 2023
- "SEC Releases Pay Versus Performance Disclosure Requirements For Public Companies," September 19, 2022
- "SEC Proposes Amendments to Schedule 13 Beneficial Ownership Reporting Requirements," February 24, 2022
- "SEC Amends Definitions of "Accelerated Filer" and "Large Accelerated Filer" and Provides Relief to Small Issuers from Auditor Attestation Requirements," March 18, 2020
- "SEC Administrative Proceedings Against Public Companies for Failure to Remediate Material Weaknesses in Internal Control Over Financial Reporting," February 5, 2019
- "Expansion of Regulation A to Reporting Companies: Increased Alternatives Now Available to Public Companies Seeking to Raise Capital or for Mergers and Acquisitions," February 1, 2019
- "The Effects of the SEC Shutdown on the Capital Markets," January 18, 2019
- "SEC Expands the Definition of 'Smaller Reporting Company,'" July 12, 2018

Cannabis Law Blog Posts

- "Reclassifying Cannabis as a Schedule III Substance – Will the DEA Agree?," August 31, 2023
- "FDA Commissioner Signals Enforcement Policy, Advancement of Research for CBD Products," March 9, 2020

Media Mentions

Majesco's \$12 Million Acquisition of InsPro Technologies
Global Legal Chronicle, 02.24.2020

Genprex's \$8 Million Common Stock Offering
Global Legal Chronicle, 02.22.2020

Aridis Pharmaceuticals' \$26 Million Initial Public Offering
Global Legal Chronicle, 09.25.2018

Speaking Engagements

Panelist, "IPO, SPAC or Reverse Merger and At-The-Market, Registered Direct Offerings or a PIPE," Planet Microcap Showcase, Las Vegas, NV, 2023

Panelist, "Key Considerations for Deal Flow and Corporate Transactions in 2023," South Asian Bar Association of North America, The Next Revolution, Boston, MA, 2023

Events

ThinkEquity Conference
The Mandarin Oriental Hotel 80 Columbus Circle (at 60th St) New York, 10023, 10.26.2022

Memberships

- Board Member, Ms. JD, Mentor
- Leadership Counsel on Legal Diversity

Practices

Corporate
Capital Markets
Public Company Corporate Governance and Compliance
Mergers and Acquisitions

Industries

Life Sciences
Healthcare
Cannabis
Food and Beverage

Education

J.D., California Western School of Law, 2013, *with honors*
B.S., George Mason University, 2010, *cum laude*

Admissions

Texas

New York

New Jersey

District of Columbia

Languages

Hindi

Urdu